T1	Participants 668 746	patients (aged 18-75 years) with, or with high risk of, coronary heart disease
T2	Participants 926 952	Patients and investigators
T3	Participants 1489 1596	189 patients were screened and 130 randomly assigned to placebo (66 patients) or dalcetrapib (64 patients).
